HEALTHSTAT NEWS
STAT+: Will Makary’s FDA voucher program survive?
RevMed’s experimental pancreatic cancer drug, daraxonrasib, is available through an expanded access program but remains unapproved. The FDA’s voucher program led by Marty Makary may undergo changes.
Related Signal
Adjacent reporting
- STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- Experimental pill promises new hope for deadly pancreatic cancer
- STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
- STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
- Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival